Health · Medical Research · 11 hrs ago

GLP-1 drugs linked to heart improvements in patients with obesity

GLP-1 drugs linked to heart improvements in patients with obesity

Mayo Clinic researchers found heart improvements linked to GLP-1 drugs in patients with obesity and heart failure.

The main study included people whose heart’s left ventricle was weak and did not pump blood effectively.

After one year, the 146 patients taking semaglutide or tirzepatide had greater improvements in heart size, structure and function than 237 similar patients who were not taking the drugs.

The findings do not show that the drugs alone caused the changes, though many improvements remained significant after researchers accounted for weight loss.

A separate study found benefits from semaglutide in people with obesity and a different type of heart failure, including heart failure remission in more than half of treated patients.

Researchers also reported exploratory results suggesting some improvements continued into a second year, but said these could guide future studies.

Lilly said Zepbound may reduce later health care use, but its analysis did not account for what patients paid for the drug, which can cost more than $1,000 a month without insurance.

1 source

Related